Sicca syndrome in the same family – the importance of anti-Ro60, anti-Ro52 and anti-La antibody profiling in Sjögren’s syndrome
Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland
Data nadesłania: 31-05-2021
Data ostatniej rewizji: 30-11--0001
Data akceptacji: 12-08-2021
Data publikacji online: 20-08-2021
Data publikacji: 02-09-2021
Reumatologia 2021;59(4):260-264
Sicca syndrome, which is typical for Sjögren’s syndrome (SS), is relatively often comorbid with other autoimmune diseases. The current classification criteria for SS published in 2016 include only anti-SSA (anti-Ro) autoantibody, while the latest literature proposes that anti-Ro60/anti-Ro52 autoantibody profiles should be used instead, as these two types of antibodies correlate with specific clinical symptoms and laboratory test findings. The paper presents the case of a 41-year-old woman suffering from primary Sjögren’s syndrome (pSS) and her three daughters, who were under observation for rheumatic disorders due to sicca symptoms, especially pSS, as well as a discussion on separate determination of anti-Ro60 and anti-Ro52 autoantibodies based on current literature in the PubMed database. When testing with antinuclear antibodies, the Ro60+Ro52+La+ autoantibody profile most closely matches for pSS. Further research is needed to find marker antibodies for SS and quantification methods.
Świerkocka K, Łącki JK. Chłoniaki w zespole Sjögrena. Reumatologia 2008; 46: 16–20.
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69: 35–45, DOI: 10.1002/art.39859.
Zappi E, Sontheimer R. Clinical relevance of antibodies to Ro/SS-A and La/SS-B in subacute cutaneous lupus erythematosus and related conditions. Immunol Invest 1993; 22: 189–203, DOI: 10.3109/08820139309063402.
Didier K, Bolko L, Giusti D, et al. Autoantibodies associated with connective tissue disease: what meaning for clinicians? Front Immunol 2018; 9: 541, DOI: 10.3389/fimmu.2018.00541.
Ghillani P, André C, Toly C, et al. Clinical significance of anti- Ro52 (TRIM21) antibodies nonassociated with anti-SSA 60 kDa antibodies: results of a multicenter study. Autoimmun Rev 2011; 10: 509–513, DOI: 10.1016/j.autrev.2011.03.004.
Dugar M, Cox S, Limaye V, et al. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010; 86: 79–82, DOI: 10.1136/pgmj.2009.089656.
Spoerl D, Roux-Lombard P. Are antibodies against La (SSB) no longer useful for the diagnosis of Sjogren’s syndrome? Clin Exp Rheumatol 2019; 37 (Suppl 118): 252–253.
Robbins A, Hentzien M, Toquet S, et al. Diagnostic utility of separate anti-Ro60 and anti-Ro52/TRIM21 antibody detection in autoimmune diseases. Front Immunol 2019; 10: 444, DOI: 10.3389/fimmu.2019.00444.
Zampeli E, Mavrommati M, Moutsopoulos HM, Skopouli FN. Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations. Clin Exp Rheumatol 2020; 38 (Suppl 126): 134–141.
Gal I, Lakos G, Zeher M. Comparison of the anti-Ro/SSA autoantibody profile between patients with primary and secondary Sjögren’s syndrome. Autoimmunity 2000; 32: 89–92, DOI: 10.3109/08916930008994077.
Song JS, Do JH, Lee SW. The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren’s syndrome. Rheumatol Int 2012; 32: 491–495, DOI: 10.1007/s00296-010-1790-x.
Gkoutzourelas A, Liaskos C, Mytilinaiou MG, et al. Anti-Ro60 seropositivity determines anti-Ro52 epitope mapping in patients with systemic sclerosis. Front Immunol 2018; 9: 2835, DOI: 10.3389/fimmu.2018.02835.
Meek B, Kelder JC, Claessen AME, et al. Rheumatoid factor isotype and Ro epitope distribution in primary Sjogren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca. Rheumatol Int 2018; 38: 1487–1493, DOI: 10.1007/s00296-018-4090-5.
Peene I, Meheus L, Veys EM. Diagnostic associations in a large consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated disease differs according to the detailed serotype. Ann Rheum Dis 2002; 61: 1090–1094, DOI: 10.1136/ard.61.12.1090.
La Paglia GMC, Sanchez-Pernaute O, Alunno A, et al. Ultrasound salivary gland involvement in Sjogren’s syndrome vs. other connective tissue diseases: is it autoantibody and gland dependent? Clin Rheumatol 2020; 39: 1207–1215, DOI: 10.1007/s10067-019-04780-2.
Menéndez A, Gómez J, Escanlar E, et al. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity 2013; 46: 32–39, DOI: 10.3109/08916934.2012.732131.
Park Y, Lee J, Koh JH, et al. Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren’s syndrome: data from a nationwide cohort for Sjögren’s syndrome in Korea. Clin Exp Rheumatol 2019; 37 (Suppl 118): 107–113.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top